Cargando…
Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer
BACKGROUND: The purpose of this study was to explore gene copy number (GCN) variation of EGFR, HER2, c-MYC, and MET in patients with primary colorectal cancer (CRC). METHODS: Dual-colour silver-enhanced in situ hybridization was performed in tissue samples of 334 primary CRC patients. The amplificat...
Autores principales: | Kwak, Yoonjin, Yun, Sumi, Nam, Soo Kyung, Seo, An Na, Lee, Kyu Sang, Shin, Eun, Oh, Heung-Kwon, Kim, Duck Woo, Kang, Sung Bum, Kim, Woo Ho, Lee, Hye Seung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540452/ https://www.ncbi.nlm.nih.gov/pubmed/28764718 http://dx.doi.org/10.1186/s12967-017-1265-x |
Ejemplares similares
-
HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
por: Seo, An Na, et al.
Publicado: (2014) -
c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer
por: Lee, Kyu Sang, et al.
Publicado: (2015) -
BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
por: Nam, Soo Kyung, et al.
Publicado: (2016) -
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
por: Press, Michael F., et al.
Publicado: (2018) -
Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
por: Kim, Gilhyang, et al.
Publicado: (2016)